A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis

NCT03418493 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: LY3316531 - IV
DRUG: LY3316531 - SC
DRUG: Placebo - IV

Sponsor

Eli Lilly and Company